To date, only a few reports have examined the potential functions of METTL1 in immunotherapy for prostate cancer and ICC, while systematic pan-cancer analyses-such as evaluating the correlation between METTL1 expression and ICI efficacy using TCGA datasets-are lacking. This evidence concerns the gene METTL1 and Familial prostate cancer.